# Omeros Corporation clinical trials: 25 (November 2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 25 trials with Omeros Corporation as lead sponsor, 1 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by Omeros Corporation: 25 rows for $5, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email.

Buy: https://specstream.ai/data/clinical-trials/company/omeros-corporation

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 25
- Recruiting or not yet: 1
- Read on: November 19, 2026

## Trials

The 25 newest of 25, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| March 7, 2024 | NCT06298955 | Long-Term Safety, Tolerability and Efficacy of OMS906 in Paroxysmal Nocturnal Hemoglobinuria | Omeros Corporation | Phase 2 | Active not recruiting | Paroxysmal Nocturnal Hemoglobinuria | 25 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06298955) |
| January 17, 2024 | NCT06209736 | Safety and Efficacy Study of OMS906 in Patients With C3G and ICGN | Omeros Corporation | Phase 2 | Terminated | C3 Glomerulopathy, Idiopathic Immune Complex-Mediated Glomerulonephritis | 3 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06209736) |
| August 2, 2023 | NCT05972967 | Safety and Efficacy of OMS906 in Paroxysmal Nocturnal Hemoglobinuria Patients With a Sub-optimal Response to Ravulizumab | Omeros Corporation | Phase 2 | Completed | Paroxysmal Nocturnal Hemoglobinuria | 12 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05972967) |
| June 5, 2023 | NCT05889299 | Study of the Safety and Efficacy of OMS906 in Patients With Paroxysmal Nocturnal Hemoglobinuria | Omeros Corporation | Phase 1 | Completed | Paroxysmal Nocturnal Hemoglobinuria | 15 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05889299) |
| May 11, 2023 | NCT05855083 | Efficacy and Safety Study of Narsoplimab in Pediatric Patients With High-Risk Hematopoietic Stem Cell Transplant TMA | Omeros Corporation | Phase 2 | Recruiting | Thrombotic Microangiopathies, Hematopoietic Stem Cell Transplantation | 18 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05855083) |
| January 30, 2020 | NCT04247906 | Single Patient Expanded Access Treatment Plan For The Investigational Product Narsoplimab | Omeros Corporation | Not applicable | Approved for marketing | Hematopoietic Stem Cell Transplant Associated Thrombotic Microangiopathy (HSCT-TMA) | Not listed | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04247906) |
| July 31, 2018 | NCT03608033 | Study of the Safety and Efficacy of OMS721 in Patients With Immunoglobulin A (IgA) Nephropathy | Omeros Corporation | Phase 3 | Terminated | IgA Nephropathy | 360 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03608033) |
| July 2, 2017 | NCT03205995 | Safety and Efficacy Study of OMS721 in Patients With Atypical Hemolytic Uremic Syndrome | Omeros Corporation | Phase 3 | Terminated | Thrombotic Microangiopathies, Atypical Hemolytic Uremic Syndrome | 6 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03205995) |
| February 15, 2016 | NCT02682407 | Safety Study of IgAN, LN, MN, & C3 Glomerulopathy Including Dense Deposit Disease Treated With OMS721 | Omeros Corporation | Phase 2 | Terminated | IgAN, LN, MN, C3G | 31 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02682407) |
| August 21, 2014 | NCT02222545 | Safety and Efficacy Study of OMS721 in Patients With Thrombotic Microangiopathies | Omeros Corporation | Phase 2 | Completed | Thrombotic Microangiopathies | 58 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02222545) |
| May 7, 2014 | NCT02132312 | A Randomized Study in Children Ages Birth Through Three Years Undergoing Unilateral Cataract Extraction With or Without Lens Replacement | Omeros Corporation | Phase 3 | Completed | Unilateral Cataract Extraction, Congenital Cataract | 78 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02132312) |
| March 21, 2014 | NCT02093689 | Intraoperative Floppy Iris Syndrome Undergoing Intraocular Lens Replacement Surgery | Omeros Corporation | Phase 3 | Terminated | Intraocular Lens Replacement, Intraoperative Floppy Iris Syndrome | 18 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02093689) |
| February 28, 2014 | NCT02074410 | Safety and Efficacy of OMS643762 in Subjects With Huntington's Disease | Omeros Corporation | Phase 2 | Terminated | Huntington's Disease | 22 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02074410) |
| September 27, 2013 | NCT01952132 | Safety, Tolerability, and Pharmacokinetics of OMS643762 in Psychiatrically Stable Schizophrenia Subjects | Omeros Corporation | Phase 2 | Completed | Schizophrenia | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01952132) |
| April 18, 2012 | NCT01579565 | Safety, Efficacy and Pharmacokinetics of OMS302 in Subjects Undergoing Intraocular Lens Replacement With Phacoemulsification | Omeros Corporation | Phase 3 | Completed | Intraocular Lens Replacement | 416 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01579565) |
| October 18, 2011 | NCT01454063 | Safety and Efficacy of OMS302 in Subjects Undergoing Intraocular Lens Replacement With Phacoemulsification | Omeros Corporation | Phase 3 | Completed | Intraocular Lens Replacement | 405 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01454063) |
| August 1, 2011 | NCT01406561 | Safety and Efficacy of OMS103HP-S Administered in Joint Irrigation Solution to Subjects Undergoing Arthroscopic Meniscectomy | Omeros Corporation | Phase 3 | Completed | Meniscal Tear | 344 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01406561) |
| September 1, 2010 | NCT01193127 | Safety and Efficacy of OMS302 in Subjects Undergoing Unilateral Cataract Extraction With Lens Replacement (CELR) | Omeros Corporation | Phase 2 | Completed | Cataract | 223 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01193127) |
| March 6, 2009 | NCT00857090 | Pharmacokinetic, Safety and Efficacy Study of OMS201 in Subjects Undergoing Retrograde Ureteroscopic Removal of Upper Urinary Tract Stones | Omeros Corporation | Phase 1/2 | Completed | Urinary Calculi, Urinary Stones, Urinary Tract Stones, Renal Calculi, Kidney Stones | 18 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00857090) |
| July 24, 2008 | NCT00721695 | Exploratory Study of OMS302 Injection in Subjects Undergoing Unilateral Cataract Extraction by Phacoemulsification. | Omeros Corporation | Phase 1/2 | Completed | Cataract Extraction | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00721695) |
| February 27, 2008 | NCT00624845 | Double-Blind, Multicenter, Study Comparing the Efficacy and Safety of OMS103HP With Vehicle Irrigation Solution in Subjects Undergoing... | Omeros Corporation | Phase 2/3 | Completed | Postoperative Pain | 200 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00624845) |
| January 24, 2008 | NCT00599664 | Pharmacokinetic and Safety Study of OMS201 in Subjects Undergoing Ureteroscopic Treatment for Removal of Urinary Tract-Located Stones | Omeros Corporation | Phase 1 | Completed | Urinary Calculi, Urinary Stones, Urinary Tract Stones | 11 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00599664) |
| October 27, 2005 | NCT00245271 | Safety of OMS103HP in Patients Undergoing Anterior Cruciate Ligament (ACL) Reconstruction | Omeros Corporation | Phase 3 | Completed | Anterior Cruciate Ligament Reconstruction | 480 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00245271) |
| September 27, 2005 | NCT00226772 | Efficacy and Safety of OMS103HP in Patients Undergoing Autograft Anterior Cruciate Ligament (ACL) Reconstruction | Omeros Corporation | Phase 3 | Completed | Knee Injuries | 326 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00226772) |
| September 27, 2005 | NCT00226759 | Efficacy and Safety of OMS103HP in Patients Undergoing Allograft Anterior Cruciate Ligament (ACL) Reconstruction | Omeros Corporation | Phase 3 | Completed | Knee Injuries | 321 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00226759) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 2 |
| Phase 1/2 | 2 |
| Phase 2 | 9 |
| Phase 2/3 | 1 |
| Phase 3 | 10 |
| Not applicable | 1 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 16 |
| Terminated | 6 |
| Active not recruiting | 1 |
| Recruiting | 1 |
| Approved for marketing | 1 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Cataract | 5 |
| Hemoglobinuria, Paroxysmal | 3 |
| Thrombotic Microangiopathies | 3 |
| Urinary Calculi | 2 |
| Calculi | 2 |
| Glomerulonephritis, IGA | 2 |
| Knee Injuries | 2 |
| Atypical Hemolytic Uremic Syndrome | 2 |
| Pain, Postoperative | 2 |
| Proteinuria | 1 |
| Renal Insufficiency, Chronic | 1 |
| Schizophrenia | 1 |
| Lupus Nephritis | 1 |
| Glomerulonephritis, Membranous | 1 |
| Huntington Disease | 1 |
| Kidney Calculi | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [TV service providers in the United States](https://specstream.ai/data/businesses/tv-service-providers/united-states)
- [Wholesalers in the United States](https://specstream.ai/data/businesses/wholesalers/united-states)
- [Appliance manufacturers in the United States](https://specstream.ai/data/businesses/appliance-manufacturers/united-states)
- [B2B newspaper advertising companies in the United States](https://specstream.ai/data/businesses/b2b-newspaper-advertising-companies/united-states)
- [Billing services in the United States](https://specstream.ai/data/businesses/billing-services/united-states)
- [Caribbean restaurants in the United States](https://specstream.ai/data/businesses/caribbean-restaurants/united-states)
